159 related articles for article (PubMed ID: 35114188)
1. Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration.
Nakai T; Saigusa D; Iwamura Y; Matsumoto Y; Umeda K; Kato K; Yamaki H; Tomioka Y; Hirano I; Koshiba S; Yamamoto M; Suzuki N
Biochem Pharmacol; 2022 Mar; 197():114939. PubMed ID: 35114188
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
3. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
Katagiri N; Hitomi H; Mae SI; Kotaka M; Lei L; Yamamoto T; Nishiyama A; Osafune K
Sci Rep; 2021 Feb; 11(1):3936. PubMed ID: 33594180
[TBL] [Abstract][Full Text] [Related]
4. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
5. The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1
Jatho A; Zieseniss A; Brechtel-Curth K; Guo J; Böker KO; Salinas G; Wenger RH; Katschinski DM
Cells; 2022 Feb; 11(4):. PubMed ID: 35203399
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
7. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-β1 decreases erythropoietin production through repressing hypoxia-inducible factor 2α in erythropoietin-producing cells.
Shih HM; Pan SY; Wu CJ; Chou YH; Chen CY; Chang FC; Chen YT; Chiang WC; Tsai HC; Chen YM; Lin SL
J Biomed Sci; 2021 Nov; 28(1):73. PubMed ID: 34724959
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
11. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
Yasuoka Y; Izumi Y; Fukuyama T; Omiya H; Pham TD; Inoue H; Oshima T; Yamazaki T; Uematsu T; Kobayashi N; Shimada Y; Nagaba Y; Yamashita T; Mukoyama M; Sato Y; Wall SM; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164384
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Renal Anemia in Patients With Hemodialysis Using Hypoxia-inducible Factor (HIF) Stabilizer, Roxadustat: A Short-term Clinical Study.
Mima A; Horii Y
In Vivo; 2022; 36(4):1785-1789. PubMed ID: 35738640
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
[TBL] [Abstract][Full Text] [Related]
15. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.
Eleftheriadis T; Pissas G; Mavropoulos A; Nikolaou E; Filippidis G; Liakopoulos V; Stefanidis I
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):31. PubMed ID: 33011826
[TBL] [Abstract][Full Text] [Related]
16. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Huang H; Wang X; Zhang X; Wang H; Jiang W
Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
[TBL] [Abstract][Full Text] [Related]
18. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
20. Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation.
Zhou Y; Chen XX; Zhang YF; Lou JZ; Yuan HB
Intern Emerg Med; 2021 Nov; 16(8):2193-2199. PubMed ID: 34021853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
